The past few days haven't been kind to most stocks in the white-hot obesity drugs space. One developer of a weight loss ...

Novo Nordisk and Eli Lilly are obvious targets, as both have such treatments already on the market, but clinical-stage players also took it on the chin -- hence the whack absorbed by Structure.

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The situation is causing the FDA regulatory headaches and, more seriously, posing ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

Political uncertainty in some of the largest European economies has diminished their growth outlook. Read more here.

Notably, in January 2025, Novo Nordisk’s semaglutide-based GLP-1 drugs ... Inc., Viking Therapeutics, Structure Therapeutics Inc., and Zealand Pharma A/S are assigned Morningstar Quantitative ...

The type 2 diabetes medication, generically known as semaglutide, has received unprecedented ... In the 1990s, Lotte Bjerre Knudsen, a Novo Nordisk researcher who previously studied detergent ...